Related Experiment Video
Updated: May 2, 2026
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.0K
Incretin therapy and heart failure.
1Departments of Advanced Cardiology, Saga University Faculty of Medicine.
Summary
Incretin-based therapies, like glucagon-like peptide-1 (GLP-1) drugs, show promise for type 2 diabetes (T2DM) patients with cardiovascular disease. While experimental data suggest heart benefits, clinical evidence is still limited.
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Medicine
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a major risk factor for cardiovascular disease (CVD), contributing significantly to morbidity and mortality.
- Incretin-based therapies, targeting glucagon-like peptide-1 (GLP-1) and related pathways, offer improved glycemic control and reduced hypoglycemia risk compared to traditional T2DM treatments.
- Preclinical studies indicate potential cardioprotective effects of GLP-1 and its analogs against atherosclerosis and cardiac dysfunction.
Purpose of the Study:
- To review the current evidence on the impact of GLP-1-related therapies on cardiac function in patients with cardiovascular disease.
- To explore the potential mechanisms underlying the cardioprotective effects of incretin-based treatments.
- To bridge the gap between experimental findings ('bench') and clinical application ('bed') for GLP-1 therapy in CVD patients.
Main Methods:
- Comprehensive literature review of experimental (in vitro and in vivo) and clinical studies.
- Analysis of data focusing on the effects of GLP-1 and related drugs on cardiovascular outcomes and cardiac function.
- Discussion of proposed molecular and cellular mechanisms of action.
Main Results:
- Extensive experimental data support cardioprotective roles for GLP-1-related therapies in models of atherosclerosis and cardiac dysfunction.
- Clinical evidence demonstrating the efficacy of these therapies specifically in patients with established cardiovascular disease remains limited.
- GLP-1 receptor agonists and related agents have shown potential in improving glycemic control and offering cardiovascular benefits.
Conclusions:
- GLP-1-related therapies present a promising avenue for managing T2DM patients with comorbid cardiovascular conditions.
- Further robust clinical trials are essential to confirm the cardioprotective efficacy and establish the role of incretin therapy in this high-risk population.
- Understanding the underlying mechanisms is crucial for optimizing therapeutic strategies and patient selection.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
01:30Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:22Heart Failure Drugs: Diuretics
1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K